Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: RTOG 1205 Principal Investigator: Huang, Jiayi
Title: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Phase: II Disease Site: Brain & Nervous System
Participating Site(s):
 
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this research study is to determine whether adding radiation to bevacizumab is more effective than using bevacizumab alone to treat recurrent glioblastomas. Bevacizumab is a commercially available drug that is FDA approved for the treatment of glioblastoma that has returned after treatment (recurrent glioblastoma). However, treatment with bevacizumab alone
has only modestly improved survival in patients with this type of brain tumor. For this reason, researchers are evaluating other treatments, including bevacizumab combined with radiation.
 
More Information:
Internal Protocol Documents (requires Siteman administrative database password)